Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. Led by The First Affiliated Hospital with Nanjing Medical University and Peking University Cancer Hospital \& Institute (as leading centers), its main purpose is to evaluate the clinical efficacy and safety of Nimotuzumab combined with nab-paclitaxel plus gemcitabine (AG) in the perioperative treatment of high-risk resectable/borderline resectable pancreatic cancer.

NCT Number	NCT07277452
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University Collaborators: Peking University Cancer Hospital & Institute
Conditions	Pancreatic Cancer, Adult
Enrollment	156 participants
Start Date	2025-12-10
Primary Completion	2028-12-10 (estimated)
Study Completion	2029-12-10 (estimated)
Updated on ClinicalTrials.gov	2025-12-11